Press Releases Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Real-time Estimate Cboe BZX Other stock markets 01:53:44 2024-05-06 pm EDT			5-day change	1st Jan Change
3.37 ^USD	-1.46%		+8.23%	+21.12%

Mar. 28	Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	MT
Mar. 28	Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	Mar. 27	AQ
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	Mar. 20	AQ
Cellectar Biosciences : Corporate Presentation - March 2024	Mar. 18	PU
Cellectar Biosciences to Present at the 36th Annual Roth Conference	Mar. 14	AQ
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	Mar. 04	AQ
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 07	AQ
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	Jan. 30	AQ
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	Jan. 25	AQ
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	Jan. 23	AQ
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient	Jan. 22	AQ
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	Jan. 17	AQ
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data	Jan. 16	AQ
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results	Jan. 15	AQ
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results	Jan. 12	AQ
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting	Jan. 11	AQ
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia	Jan. 08	AQ
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024	Jan. 03	AQ
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation	Dec. 19	AQ
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform	Dec. 12	AQ
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe	Dec. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Press Releases

Filters